Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy
Marshall Winget(Vanderbilt University Medical Center), Lindsay Orton(Vanderbilt University), Andrew Jallouk(Vanderbilt University Medical Center), Eden Biltibo(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University), James H. Jerkins(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Adetola A. Kassim(Vanderbilt University), Elizabeth McNeer(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Tae Kon Kim(Vanderbilt University), Wichai Chinratanalab(VA Tennessee Valley Healthcare System), Katie S. Gatwood(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Leena Choi(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Kendall C. Shultes(Unknown), Hunter Sowell(Vanderbilt University Medical Center), Jana Sawyer(VA Tennessee Valley Healthcare System), R.M. Gilmore(Vanderbilt University Medical Center)
Cited by 3
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416